Human adipose stem cell-derived extracellular nanovesicles for treatment of chronic liver fibrosis
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Liver fibrosis is an excessive wound healing process that occurs in response to liver damage depending on underlying aetiologies. Currently, there are no effective therapies and FDA-approved therapeutics for the treatment of liver fibrosis except liver transplantation. Multipotent adipose-derived stem cells (ADSCs) have received significant attention as regenerative medicine for liver fibrosis owing to their advantages over stem cells with other origins. However, intrinsic limitations of stem cell therapies, such as cellular rejection and tumor formation, have impeded clinical applications of the ADSC-based liver therapeutics. To overcome these problems, the extracellular nanovesicles (ENVs) responsible for the therapeutic effect of ADSCs (A-ENVs) have shown considerable promise as cell-free therapeutics for liver diseases. However, A-ENVs have not been used for the treatment of intractable chronic liver diseases including liver fibrosis and cirrhosis. Therefore, in this study, we investigated the in vitro and in vivo antifibrotic efficacy of A-ENVs in thioacetamide-induced liver fibrosis models. A-ENVs significantly downregulated the expression of fibrogenic markers, such as matrix metalloproteinase-2, collagen-1, and alpha-smooth muscle actin. The systemic administration of A-ENVs led to high accumulation in fibrotic liver tissue and the restoration of liver functionality in liver fibrosis models through a marked reduction in α-SMA and collagen deposition. These results demonstrate the significant potential of A-ENVs for use as extracellular nanovesicles-based therapeutics in the treatment of liver fibrosis and possibly other intractable chronic liver diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kern, S., Eichler, H., Stoeve, J., Klüter, H., & Bieback, K. (2006) · STEM CELLS · doi:10.1634/stemcells.2005-0342 · Cited by 3,370
Concise review: MSC-derived exosomes for cell-free therapy
Phinney, D. G., & Pittenger, M. F. (2017) · Stem Cells · doi:10.1002/stem.2575 · Cited by 1,834
Pathogenesis of Liver Fibrosis
Hernandez-Gea, V., & Friedman, S. L. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130246 · Cited by 1,809
Liver fibrosis – from bench to bedside
Friedman, S. L. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00429-4 · Cited by 1,780
Caplan, A. I., & Correa, D. (2011) · Cell Stem Cell · doi:10.1016/j.stem.2011.06.008 · Cited by 1,682
Ortiz, L. A., DuTreil, M., Fattman, C., Pandey, A. C., Torres, G., Go, K., & Phinney, D. G. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704421104 · Cited by 1,019
Tan, C. Y., Lai, R. C., Wong, W., Dan, Y. Y., Lim, S.-K., & Ho, H. K. (2014) · Stem Cell Research & Therapy · doi:10.1186/scrt465 · Cited by 548
Huang, B., Cheng, X., Wang, H., Huang, W., la Ga hu, Z., Wang, D., Zhang, K., Zhang, H., Xue, Z., Da, Y., et al. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-0792-1 · Cited by 183
Microencapsulated human mesenchymal stem cells decrease liver fibrosis in mice
Meier, R. P. H., Mahou, R., Morel, P., Meyer, J., Montanari, E., Muller, Y. D., Christofilopoulos, P., Wandrey, C., Gonelle-Gispert, C., & Bühler, L. H. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.10.030 · Cited by 153
Fibrotic microtissue array to predict anti-fibrosis drug efficacy
Asmani, M., Velumani, S., Li, Y., Wawrzyniak, N., Hsia, I., Chen, Z., Hinz, B., & Zhao, R. (2018) · Nature Communications · doi:10.1038/s41467-018-04336-z · Cited by 137
Cited by
The Role of MSC in Wound Healing, Scarring and Regeneration
Guillamat-Prats, R. (2021) · Cells · doi:10.3390/cells10071729 · Cited by 393
Extracellular vesicles: a rising star for therapeutics and drug delivery
Du, S., Guan, Y., Xie, A., Yan, Z., Gao, S., Li, W., Rao, L., Chen, X., & Chen, T. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01973-5 · Cited by 314
Li, Y., Zhang, J., Shi, J., Liu, K., Wang, X., Jia, Y., He, T., Shen, K., Wang, Y., Liu, J., et al. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02290-0 · Cited by 266
Mesenchymal Stem Cell–Derived Exosomes in Various Chronic Liver Diseases: Hype or Hope?
Zhu, L., Wang, Q., Guo, M., Fang, H., Li, T., Zhu, Y., Jiang, H., Xiao, P., & Hu, M. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s439974 · Cited by 21
Smart Microneedle Arrays Integrating Cell‐Free Therapy and Nanocatalysis to Treat Liver Fibrosis
Xu, Y., Zhang, Y., Tian, H., Zhong, Q., Yi, K., Li, F., Xue, T., Wang, H., Lao, Y., Xu, Y., et al. (2024) · Advanced Science · doi:10.1002/advs.202309940 · Cited by 19
Metadata
- Authors
- Han, H. S., Lee, H., You, D., Nguyen, V. Q., Song, D.-G., Oh, B. H., Shin, S., Choi, J. S., Kim, J. D., Pan, C.-H., Jo, D.-G., Cho, Y. W., Choi, K. Y., & Park, J. H.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2020-04
- Volume
- 320
- Pages
- 328-336
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W3002444392
- Cited by
- 58
- References
- 10
- FWCI
- 2.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Human adipose stem cell-derived extracellular nanovesicles for treatment of chronic liver fibrosis. https://app.cochat.ai/papers/10.1016/j.jconrel.2020.01.042
- The paper
- Han, H. S., Lee, H., You, D., Nguyen, V. Q., Song, D.-G., Oh, B. H., Shin, S., Choi, J. S., Kim, J. D., Pan, C.-H., Jo, D.-G., Cho, Y. W., Choi, K. Y., & Park, J. H. (2020). Human adipose stem cell-derived extracellular nanovesicles for treatment of chronic liver fibrosis. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2020.01.042
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.